Caris Life Sciences and COTA, Inc. Team Up to Broaden Collective Multi-Modal Data Offerings
Wednesday, May 01, 2024
Caris Life Sciences® (Caris), a leader in AI TechBio and precision medicine, has partnered with COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics firm, to enhance their multi-modal data offerings. Their collaboration aims to advance biopharmaceutical drug development and patient care through a comprehensive array of data resources.
Caris brings extensive genomic, transcriptomic, proteomic, and imaging data, accumulated through its work in molecular science and AI. Meanwhile, COTA offers curated clinical data, capturing the treatment journeys and outcomes of cancer patients. Together, they aim to provide a real-world data platform driving advancements in cancer therapeutics.
Caris, emphasized the partnership's significance, enabling biopharma with a more comprehensive dataset for research and AI-driven therapeutic development. This dataset allows for identifying key insights like mechanisms of resistance and treatment response determinants.
Caris, known for precision medicine initiatives and molecular profiling, has a vast multi-modal database from nearly 10 million tests, including Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage.
COTA, highlighted the collaboration's potential in unlocking insights for optimizing cancer treatments. By merging COTA's clinical data with Caris' molecular data, researchers can explore personalized cancer therapies.
COTA's dataset spans two million cancer patients across 200 care sites, providing a comprehensive view of cancer care across diverse settings. This empowers life sciences companies to develop personalized treatment strategies.
Source: prnewswire.com
